Pensando a proteção da propriedade intelectual em equilíbrio com o acesso ao conhecimento.
On the 17th of May, 2007, the Intellectual Property and Consumer Rights: Access to Knowledge (A2K), Culture and Information Seminar, promoted by the Center for Technology and Society (CTS) of FGV DIREITO RIOBrazilian Institute for Consumer Defense (Idec), launched the partnership between both institutions.
by Andrew Jack in London and Richard Lapper in São Paulo
May 5, 2007
Brazil yesterday overrode the patent on a pivotal HIV medicine,
becoming the second emerging economy aggressively to challenge the
pharmaceutical industry in seeking a sharp reduction in drug costs.
By Alastair Stewart
May 5, 2007
SAO PAULO — Brazilian President Luiz Inacio Lula da Silva Friday
signed a compulsory license, breaking the patent on an anti-retroviral
AIDS drug made by the U.S.
by Tove Iren S. Gerhardsen
May 7, 2007
The government of Brazil has issued a license that will allow the importation of cheaper versions of a patented HIV/AIDS drug after negotiations failed to bring about agreement on price reductions with Merck, the US company holding the patent.
by James Packard Love
May 4, 2007
On national television Brazilian President Luiz Inácio Lula Da Silva has just announced a compulsory license on patents controlled by Merck for the important AIDS drug Efavirenz.
Yesterday, for the very first time in Brazilian history, a pharmaceutical company had its patent compulsorily licensed by the Federal Government due to its public interest. Before the issuance of the compulsory license, President Luis Inacio Lula da Silva issued a decree declaring the anti-retroviral Efavirenz of public interest.
The anti-retroviral Efavirenz, used by 38% of Brazilians under AIDS treatment, is currently held by the North-American laboratory Merck Sharp & Dohme, the owner of the patent.
